Haemonetics helps health care providers keep track of blood. The company develops and produces automated blood collection systems that collect and process whole blood, taking only the components (such as plasma or red blood cells) needed and returning the remainder to the donors. Typically these systems, sold under the Cymbal or MCS brands, are bought and used by blood centers. Haemonetics also makes hospital systems that collect and re-infuse a patient's own blood during surgery; these surgical blood salvage systems are sold under the cardioPAT and Cell Saver brand names. Additionally, the company sells information management software and provides consulting services to blood banks and hospitals.
More than 80% of the company's revenues come from the sale of single-use disposable products that work with its specialized blood collection and processing systems. The balance of revenues comes from sales and maintenance of its systems and software products, and consulting services.
Haemonetics markets its products and services worldwide through a direct sales force and distributors. The company's primary markets are the US, Europe, and Japan, though it also maintains a direct sales presence in Canada and China. It uses distributors to sell its products in South America, the Middle East, and other markets. It has manufacturing facilities in the US, Scotland, and Switzerland and is supplied by third party manufacturers in Japan and Thailand.
Collecting and banking blood is easier when hospitals and banks have good software to manage the process. To meet that need, Haemonetics has built up its information management systems and services. Its subsidiary Haemonetics Software Solutions grew from the 2009 additions of Altivation Software and Neoteric Technology and in 2010 the company paid $60 million in cash to purchase Global Med Technologies, a health information technology firm.
Once it got its IT purchases squared away, Haemonetics put its attention back on actual blood processing hardware. The company spent some $550 million to acquire blood collection and processing product lines and manufacturing facilities from Pall Corporation in 2012. It also agreed to buy up the assets of Minnesota-based Hemerus Medical, a developer of innovative whole blood collection, processing, and storage equipment, in a deal worth some $27 million. – less